We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

85 hedge funds and large institutions have $123M invested in Antares Pharma, Inc. in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less funds holding

Funds holding: 91 → 85 (-6)

13% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 31

29% less capital invested

Capital invested by funds: $174M → $123M (-$51.4M)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

92% less call options, than puts

Call options by funds: $41K | Put options by funds: $498K

Holders
85
Holders Change
-6
Holders Change %
-6.59%
% of All Funds
2.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
27
Reduced
31
Closed
15
Calls
$41K
Puts
$498K
Net Calls
-$457K
Net Calls Change
-$882K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$5.48M
2
WHI
William Harris Investors
Illinois
+$2.48M
3
BC
Broadfin Capital
New York
+$2.26M
4
ACM
Ashford Capital Management
Delaware
+$687K
5
Citadel Advisors
Citadel Advisors
Florida
+$355K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$11.2M
2
Allianz Asset Management
Allianz Asset Management
Germany
-$4.32M
3
JGC
J. Goldman & Co
New York
-$3.41M
4
PWAM
Park West Asset Management
California
-$1.75M
5
KCM
Kingdon Capital Management
New York
-$978K

ATRS Hedge Fund Activity: Q2 2014 in Review

85 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2014, worth a combined $123M — down 29% from $174M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ATRS and 9 opened new positions — a net loss of 6 holders — while 31 trimmed existing stakes and 27 added.

The largest buyer was Millennium Management, adding an estimated $5.48M. The largest seller was OrbiMed, exiting entirely with an estimated $11.2M sold.

  • 85 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2014, down from 91 in Q1 2014.
  • Funds reported $123M of Antares Pharma, Inc. stock for Q2 2014, down 29% quarter-over-quarter.
  • 9 funds opened new Antares Pharma, Inc. positions in Q2 2014 and 15 closed out, a net change of -6 holders.
  • The largest Antares Pharma, Inc. buyer in Q2 2014 was Millennium Management, an estimated $5.48M added.
  • The largest Antares Pharma, Inc. seller in Q2 2014 was OrbiMed, an estimated $11.2M sold.

Based on aggregated 13F filings for Q2 2014.